Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases.
Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM. Flørenes VA, et al. Transl Oncol. 2019 Jul;12(7):951-958. doi: 10.1016/j.tranon.2019.04.001. Epub 2019 May 13. Transl Oncol. 2019. PMID: 31096111 Free PMC article.
Soluble AXL is ubiquitously present in malignant serous effusions.
Flem Karlsen K, McFadden E, Flørenes VA, Davidson B. Flem Karlsen K, et al. Among authors: florenes va. Gynecol Oncol. 2019 Feb;152(2):408-415. doi: 10.1016/j.ygyno.2018.11.012. Epub 2018 Nov 15. Gynecol Oncol. 2019. PMID: 30448261
Soluble AXL as a marker of disease progression and survival in melanoma.
Flem-Karlsen K, Nyakas M, Farstad IN, McFadden E, Wernhoff P, Jacobsen KD, Flørenes VA, Mælandsmo GM. Flem-Karlsen K, et al. Among authors: florenes va. PLoS One. 2020 Jan 9;15(1):e0227187. doi: 10.1371/journal.pone.0227187. eCollection 2020. PLoS One. 2020. PMID: 31917795 Free PMC article.
AXL inhibition improves BRAF-targeted treatment in melanoma.
Nyakas M, Fleten KG, Haugen MH, Engedal N, Sveen C, Farstad IN, Flørenes VA, Prasmickaite L, Mælandsmo GM, Seip K. Nyakas M, et al. Among authors: florenes va. Sci Rep. 2022 Mar 24;12(1):5076. doi: 10.1038/s41598-022-09078-z. Sci Rep. 2022. PMID: 35332208 Free PMC article.
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study.
Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K. Ree AH, et al. Among authors: florenes va. Acta Oncol. 2020 Jul;59(7):733-740. doi: 10.1080/0284186X.2020.1742377. Epub 2020 Mar 25. Acta Oncol. 2020. PMID: 32208873
Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis.
Slipicevic A, Øy GF, Rosnes AK, Stakkestad Ø, Emilsen E, Engesæter B, Mælandsmo GM, Flørenes VA. Slipicevic A, et al. Among authors: florenes va. Cancer Biol Ther. 2013 Feb;14(2):146-54. doi: 10.4161/cbt.22953. Epub 2012 Nov 28. Cancer Biol Ther. 2013. PMID: 23192275 Free PMC article.
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate.
Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA, Hagene KT, Aas E, Lurås H, Johnsen-Soriano S, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Mælandsmo GM, Flatmark K. Ree AH, et al. Among authors: florenes va. ESMO Open. 2017 May 2;2(2):e000158. doi: 10.1136/esmoopen-2017-000158. eCollection 2017. ESMO Open. 2017. PMID: 28761742 Free PMC article.
104 results